A human-based integrated framework for Alzheimer's disease research

Journal of Alzheimer's Disease

Volumn 47, Issue 4, 2015, Pages 857-868

  Pistollato, Francesca ^a   Cavanaugh, Sarah E ^a   Chandrasekera, P Charukeshi ^a  

^a PHYSICIANS COMMITTEE FOR RESPONSIBLE MEDICINE   (United States)

Author keywords

Alzheimer's disease; Animal models; Biomarkers; Computational methods; Human based methods; Risk factors; Stem cells; Translational gap

Indexed keywords

ALZHEIMER DISEASE; ARTICLE; CELL FUNCTION; CONCEPTUAL FRAMEWORK; ELECTRON MICROSCOPY; EPIGENETICS; GENETIC ASSOCIATION; HUMAN; HUMAN BASED INTEGRATED FRAMEWORK; INFORMATION PROCESSING; MEDICAL RESEARCH; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; STEM CELL; ANIMAL; CLINICAL TRIAL (TOPIC); DISEASE MODEL; GENETICS; PATHOPHYSIOLOGY; PROCEDURES;

ALZHEIMER DISEASE; ANIMALS; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS;

EID: 84939423652     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150281     Document Type: Article

References (138)

1. Alzheimer's Association (2013) 2013 Alzheimer's Disease Facts and Figures, http://www. alz. org/downloads/ facts figures 2013. pdf, Accessed March 19, 2015.
2. Hebert LE,Weuve J, Scherr PA,EvansDA(2013) Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology 80, 1778-1783.
3. Alzheimer's Disease International (2009) World Alzheimer Report 2009 http://www. alz. co. uk/research/files/ WorldAlzheimerReport. pdf, Accessed March 19, 2015.
4. Mayo Clinic, Alzheimer's: Drugs help manage symptoms, http://www. mayoclinic. org/diseases-conditions/alzhe imers-disease/in-depth/alzheimers/art-20048103, Accessed March 19, 2015.
5. PhRMA (2012) Researching Alzheimer's Medicines: Setbacks and Stepping Stones, http://www. phrma. org/ sites/default/files/pdf/alzheimersetbacksreportfinal912. pdf, Accessed March 19, 2015.
6. Bezprozvanny I (2010) The rise and fall of Dimebon. Drug News Perspect 23, 518-523.
7. Laurance J (2012) Drug giants give up on Alzheimer's cure. The Independent, http://www. independent. co. uk/lifestyle/ health-and-families/health-news/drug-giants-give-upon-alzheimers-cure-8153606. html, Accessed March, 19 2015.
8. Rios JA, Cisternas P, Arrese M, Barja S, InestrosaNC(2014) Is Alzheimer's disease related to metabolic syndrome? A Wnt signaling conundrum. Prog Neurobiol 121, 125-146.
9. Heininger K (2000) A unifying hypothesis of Alzheimer's disease. IV. Causation and sequence of events. Rev Neurosci 11 Spec No, 213-328.
10. Langley GR (2014) Considering a new paradigm for Alzheimer's disease research. Drug Discov Today 19, 1114-1124.
11. Bertram L, Tanzi RE (2008) Thirty years of Alzheimer's disease genetics: The implications of systematic meta-analyses. Nat Rev Neurosci 9, 768-778.
12. Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerriere A, Vital A, Dumanchin C, Feuillette S, Brice A, Vercelletto M, Dubas F, Frebourg T, CampionD(2006) APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 38, 24-26.
13. Chouraki V, Seshadri S (2014) Genetics of Alzheimer's disease. Adv Genet 87, 245-294.
14. Hollingworth P, Harold D, Jones L, Owen MJ, Williams J (2011) Alzheimer's disease genetics: Current knowl edge and future challenges. Int J Geriatr Psychiatry 26, 793-802.
15. Shibata N, Nagata T, Tagai K, Shinagawa S, Ohnuma T, Kawai E, Kasanuki K, Shimazaki H, Toda A, Tagata Y, Nakada T, Nakayama K, Yamada H,Arai H (2014) Association between the catechol-O-methyltransferase polymorphism Val158Met and Alzheimer's disease in a Japanese population. Int J Geriatr Psychiatry. doi: 10. 1002/gps. 4237
16. Peterson D, Munger C, Crowley J, Corcoran C, Cruchaga C, GoateAM,NortonMC,Green RC, Munger RG, Breitner JC, Welsh-Bohmer KA, Lyketsos C, Tschanz J, Kauwe JS, Alzheimer's Disease Neuroimaging I (2014) Variants in PPP3R1 and MAPT are associated with more rapid functional decline in Alzheimer's disease: The Cache County Dementia Progression Study. Alzheimers Dement 10, 366-371.
17. Barberger-Gateau P, Lambert JC, Feart C, Peres K, Ritchie K, Dartigues JF, Alperovitch A (2013) From genetics to dietetics: The contribution of epidemiology to understanding Alzheimer's disease. J Alzheimers Dis 33 (Suppl 1), S457-S463.
18. Ballatore C, Lee VM, Trojanowski JQ (2007) Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 8, 663-672.
19. Choi SH, Kim YH, Hebisch M, Sliwinski C, Lee S, D'Avanzo C, Chen H, Hooli B, Asselin C, Muffat J, Klee JB, Zhang C, Wainger BJ, Peitz M, Kovacs DM, Woolf CJ, Wagner SL, Tanzi RE,Kim DY (2014) A three-dimensional human neural cell culture model of Alzheimer's disease. Nature 515, 274-278.
20. Tanzi RE (2012) The genetics of Alzheimer disease. Cold Spring Harb Perspect Med 2, pii: a006296.
21. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron 39, 409-421.
22. Duyckaerts C, Potier MC, Delatour B (2008) Alzheimer disease models and human neuropathology: Similarities and differences. Acta Neuropathol 115, 5-38.
23. Cavanaugh SE, Pippin JJ, Barnard ND (2014) Animal models of Alzheimer disease: Historical pitfalls and a path forward. ALTEX 31, 279-302.
24. Livesey FJ (2012) Stem cell models of Alzheimer's disease and related neurological disorders. Alzheimers Res Ther 4, 44.
25. Hartung T (2013) Look back in anger-what clinical studies tell us about preclinical work. ALTEX 30, 275-291.
26. Drzezga A (2009) Diagnosis of Alzheimer's disease with 18F PET in mild and asymptomatic stages. Behav Neurol 21, 101-115.
27. Chai CK (2007) The genetics of Alzheimer's disease. Am J Alzheimers Dis Other Demen 22, 37-41.
28. Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S, Fiske A, Pedersen NL (2006) Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 63, 168-174.
29. Rossor MN, Fox NC, Freeborough PA, Harvey RJ (1996) Clinical features of sporadic and familial Alzheimer's disease. Neurodegeneration 5, 393-397.
30. Pistollato F, Battino M (2014) Role of plant-based diets in the prevention and regression of metabolic syndrome and neurodegenerative diseases. Trends Food Sci Technol 40, 62-81.
31. RosendorffC, Beeri MS, SilvermanJM(2007) Cardiovascular risk factors for Alzheimer's disease. AmJ Geriatr Cardiol 16, 143-149.
32. Russ TC, Stamatakis E, Hamer M, Starr JM, Kivimaki M, Batty GD (2013) Socioeconomic status as a risk factor for dementia death: Individual participant meta-analysis of 86 508 men and women from the UK. Br J Psychiatry 203, 10-17.
33. Sattler C, Toro P, Schonknecht P, Schroder J (2012) Cognitive activity, education and socioeconomic status as preventive factors for mild cognitive impairment and Alzheimer's disease. Psychiatry Res 196, 90-95.
34. Paradise M, Cooper C, Livingston G (2009) Systematic review of the effect of education on survival in Alzheimer's disease. Int Psychogeriatr 21, 25-32.
35. Hernandez SS, Sandreschi PF, Silva FC, Arancibia BA, da Silva R, Gutierres PJ, Andrade A (2014) What are the benefits of exercise for Alzheimer's disease? A systematic review of past 10 years. J Aging Phys Act. doi:10. 1123/japa. 2014-0180
36. Okonkwo OC, Schultz SA, Oh JM, Larson J, Edwards D, Cook D, Koscik R, Gallagher CL, Dowling NM, Carlsson CM, Bendlin BB, LaRue A, Rowley HA, Christian BT, Asthana S, Hermann BP, Johnson SC, Sager MA (2014) Physical activity attenuates age-related biomarker alterations in preclinical AD. Neurology 83, 1753-1760.
37. Gates NJ, Sachdev P (2014) Is cognitive training an effective treatment for preclinical and early Alzheimer's disease? J Alzheimers Dis 42, S551-S559.
38. Lim MM, Gerstner JR, Holtzman DM (2014) The sleepwake cycle and Alzheimer's disease: What do we know? Neurodegener Dis Manag 4, 351-362.
39. Videnovic A, Lazar AS, Barker RA, Overeem S (2014) 'The clocks that time us'-circadian rhythms in neurodegenerative disorders. Nat Rev Neurol 10, 683-693.
40. Peter-Derex L, Yammine P, Bastuji H, Croisile B (2015) Sleep and Alzheimer's disease. Sleep Med Rev 19, 29-38.
41. LuceyBP, Bateman RJ (2014) Amyloid-beta diurnal pattern: Possible role of sleep in Alzheimer's disease pathogenesis. Neurobiol Aging 35(Suppl 2), S29-S34.
42. Ju YE, Lucey BP, Holtzman DM (2014) Sleep and Alzheimer disease pathology-a bidirectional relationship. Nat Rev Neurol 10, 115-119.
43. Moulton PV, YangW(2012) Air pollution, oxidative stress, and Alzheimer's disease. J Environ Public Health 2012, 472751.
44. Cataldo JK, Prochaska JJ, GlantzSA(2010) Cigarette smoking is a risk factor for Alzheimer's Disease: An analysis controlling for tobacco industry affiliation. J Alzheimers Dis 19, 465-480.
45. Shcherbatykh I, Carpenter DO (2007) The role of metals in the etiology of Alzheimer's disease. J Alzheimers Dis 11, 191-205.
46. Brewer GJ (2012) Copper excess, zinc deficiency, and cognition loss in Alzheimer's disease. Biofactors 38, 107-113.
47. Tong Y, Yang H, Tian X, Wang H, Zhou T, Zhang S, Yu J, Zhang T, Fan D, Guo X, Tabira T, Kong F, Chen Z, Xiao W, Chui D (2014) High manganese, a risk for Alzheimer's disease: High manganese induces amyloidbeta related cognitive impairment. J Alzheimers Dis 42, 865-878.
48. Michaud M, Balardy L, Moulis G, Gaudin C, Peyrot C, Vellas B, Cesari M, Nourhashemi F (2013) Proinflammatory cytokines, aging, and age-related diseases. J Am Med Dir Assoc 14, 877-882.
49. Obasi CN, Cruickshanks KJ, Nondahl DM, Klein BE, Klein R, Nieto FJ, Shankar A, Fischer ME, Tsai MY, Chappell R (2012) Association of biomarkers for inflammation, endothelial dysfunction and oxidative stress with cognitive impairment. The Epidemiology of Hearing Loss Study (EHLS). Oxid Antioxid Med Sci 1, 169-173.
50. Tripathy D, Sanchez A, Yin X, Luo J, Martinez J, Grammas P (2013) Thrombin, a mediator of cerebrovascular inflammation in AD and hypoxia. Front Aging Neurosci 5, 19.
51. Kamath AF, Chauhan AK, Kisucka J, Dole VS, Loscalzo J, Handy DE, Wagner DD (2006) Elevated levels of homocysteine compromise blood-brain barrier integrity in mice. Blood 107, 591-593.
52. Boldyrev A, Bryushkova E, Mashkina A, Vladychenskaya E (2013) Why is homocysteine toxic for the nervous and immune systems? Curr Aging Sci 6, 29-36.
53. Al-khateeb E, Althaher A, Al-khateeb M, Al-Musawi H, Azzouqah O, Al-Shweiki S, Shafagoj Y (2015) Relation between uric acid and Alzheimer's disease in elderly Jordanians. J Alzheimers Dis 44, 859-865.
54. Chen X, Guo X, Huang R, ChenY, Zheng Z, ShangH(2014) Serum uric acid levels in patients with Alzheimer's disease: A meta-analysis. PLoS One 9, e94084.
55. Mousavi M, Jonsson P, Antti H, Adolfsson R, Nordin A, Bergdahl J, Eriksson K, Moritz T, Nilsson LG, Nyberg L (2014) Serum metabolomic biomarkers of dementia. Dement Geriatr Cogn Dis Extra 4, 252-262.
56. Zarrouk A, Riedinger JM, Ahmed SH, Hammami S, Chaabane W, Debbabi M, Ben Ammou S, Rouaud O, Frih M, Lizard G, Hammami M (2015) Fatty acid profiles in demented patients: Identification of hexacosanoic acid (C26:0) as a blood lipid biomarker of dementia. J Alzheimers Dis 44, 1349-1359.
57. Ferreira ST, Clarke JR, Bomfim TR, De Felice FG (2014) Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease. Alzheimers Dement 10, S76-S83.
58. Willette AA, Johnson SC, Birdsill AC, Sager MA, Christian B, Baker LD, Craft S, Oh J, Statz E, Hermann BP, Jonaitis EM, Koscik RL, La Rue A, Asthana S, Bendlin BB (2015) Insulin resistance predicts brain amyloid deposition in late middle-aged adults. Alzheimers Dement 11, 504-510 e501.
59. de la Monte SM, Tong M, Lester-Coll N, PlaterMJr.,Wands JR (2006) Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: Relevance to Alzheimer's disease. J Alzheimers Dis 10, 89-109.
60. Morris JK, Vidoni ED, Honea RA, Burns JM, Alzheimer's Disease Neuroimaging I (2014) Impaired glycemia increases disease progression in mild cognitive impairment. Neurobiol Aging 35, 585-589.
61. Lozano L, Lara-Lemus R, Zenteno E, Alvarado-Vasquez N (2014) The mitochondrial O-linked N-acetylglucosamine transferase (mOGT) in the diabetic patient could be the initial trigger to develop Alzheimer disease. Exp Gerontol 58, 198-202.
62. Vitali C, Wellington CL, Calabresi L (2014) HDL and cholesterol handling in the brain. Cardiovasc Res 103, 405-413.
63. Blom K, Emmelot-Vonk MH, Koek HL (2013) The influence of vascular risk factors on cognitive decline in patients with dementia: A systematic review. Maturitas 76, 113-117.
64. Vikarunnessa S, Weiner MF, Vega GL (2013) LDL phenotype in subjects with mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 36, 571-575.
65. Reed B, Villeneuve S,MackW, DeCarli C, Chui HC, Jagust W (2014) Associations between serum cholesterol levels and cerebral amyloidosis. JAMA Neurol 71, 195-200.
66. Warren MW, Hynan LS, Weiner MF (2012) Lipids and adipokines as risk factors for Alzheimer's disease. J Alzheimers Dis 29, 151-157.
67. Ferini-Strambi L (2014) Possible role of orexin in the pathogenesis of Alzheimer disease. JAMA Neurol 71, 1478-1480.
68. Nixon JP,MavanjiV, Butterick TA, Billington CJ,Kotz CM, Teske JA(2015) Sleep disorders, obesity, and aging: The role of orexin. Ageing Res Rev 20, 63-73.
69. Adam JA, Menheere PP, van Dielen FM, Soeters PB, Buurman WA, Greve JW (2002) Decreased plasma orexin-A levels in obese individuals. Int J Obes Relat Metab Disord 26, 274-276.
70. Fronczek R, van Geest S, Frolich M, Overeem S, Roelandse FW, Lammers GJ, Swaab DF (2012) Hypocretin (orexin) loss in Alzheimer's disease. Neurobiol Aging 33, 1642-1650.
71. Antonell A, Mansilla A, Rami L, Llado A, Iranzo A, Olives J, Balasa M, Sanchez-Valle R, Molinuevo JL (2014) Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer's disease. J Alzheimers Dis 42, 901-908.
72. Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ, Mintun MA, Peskind ER, Li G, Galasko DR, Clark CM, Quinn JF, D'Angelo G, Malone JP, Townsend RR, Morris JC, Fagan AM, Holtzman DM (2010) YKL-40: A novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry 68, 903-912.
73. Engelborghs S (2013) Clinical indications for analysis of Alzheimer's disease CSF biomarkers. Rev Neurol (Paris) 169, 709-714.
74. Huded CB, Bharath S, Chandra SR, Sivakumar PT, Varghese M, Subramanian S (2015) Supportive CSF biomarker evidence to enhance the National Institute on Aging-Alzheimer's Association criteria for diagnosis of Alzheimer's type dementia-A study from Southern India. Asian J Psychiatr 13, 44-47.
75. Rappaport SM (2012) Discovering environmental causes of disease. J Epidemiol Community Health 66, 99-102.
76. Yegambaram M, Manivannan B, Beach TG, Halden RU (2015) Role of environmental contaminants in the etiology of Alzheimer's disease: A review. Curr Alzheimer Res 12, 116-146.
77. Oboudiyat C, Glazer H, Seifan A, Greer C, Isaacson RS (2013) Alzheimer's disease. Semin Neurol 33, 313-329.
78. Nicolia V, Lucarelli M, Fuso A (2015) Environment, epigenetics and neurodegeneration: Focus on nutrition in Alzheimer's disease. Exp Gerontol 68, 8-12.
79. Virmani A, Pinto L, Binienda Z, Ali S (2013) Food, nutrigenomics, and neurodegeneration-neuroprotection by what you eat! Mol Neurobiol 48, 353-362.
80. Jicha GA, Markesbery WR (2010) Omega-3 fatty acids: Potential role in the management of early Alzheimer's disease. Clin Interv Aging 5, 45-61.
81. Bourre JM (2006) Effects of nutrients (in food) on the structure and function of the nervous system: Update on dietary requirements for brain. Part 1: Micronutrients. J Nutr Health Aging 10, 377-385.
82. Feart C, Samieri C, Alles B, Barberger-Gateau P (2013) Potential benefits of adherence to the Mediterranean diet on cognitive health. Proc Nutr Soc 72, 140-152.
83. Schaffer S, Asseburg H, Kuntz S, Muller WE, Eckert GP (2012) Effects of polyphenols on brain ageing and Alzheimer's disease: Focus on mitochondria. Mol Neurobiol 46, 161-178.
84. Joseph J, Cole G, Head E, Ingram D (2009) Nutrition, brain aging, and neurodegeneration. J Neurosci 29, 12795-12801.
85. Kageyama M, Hiraoka M, Kagawa Y (2008) Relationship between genetic polymorphism, serum folate and homocysteine in Alzheimer's disease. Asia Pac J Public Health 20 Suppl, 111-117.
86. Kerchner GA (2011) Ultra-high field 7T MRI: A new tool for studying Alzheimer's disease. J Alzheimers Dis 26(Suppl 3), 91-95.
87. Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, Zhang MR, Trojanowski JQ, Lee VM, Ono M, Masamoto K, Takano H, Sahara N, Iwata N, Okamura N, Furumoto S, Kudo Y, Chang Q, Saido TC, Takashima A, Lewis J, Jang MK, Aoki I, Ito H, Higuchi M (2013) Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 79, 1094-1108.
88. Blasko I, Hinterberger M, Kemmler G, Jungwirth S, Krampla W, Leitha T, Heinz Tragl K, Fischer P (2012) Conversion from mild cognitive impairment to dementia: Influence of folic acid and vitamin B12 use in the VITA cohort. J Nutr Health Aging 16, 687-694.
89. Mosconi L, Murray J, Tsui WH, LiY,Davies M,Williams S, Pirraglia E, Spector N, Osorio RS, Glodzik L, McHugh P, de Leon MJ (2014) Mediterranean diet and magnetic resonance imaging-assessed brain atrophy in cognitively normal individuals at risk for Alzheimer's disease. J Prev Alzheimers Dis 1, 23-32.
90. Titova OE, Ax E, Brooks SJ, Sjogren P, Cederholm T, Kilander L,Kullberg J, Larsson EM, Johansson L, Ahlstrom H, Lind L, Schioth HB, Benedict C (2013) Mediterranean diet habits in older individuals: Associations with cognitive functioning and brain volumes. Exp Gerontol 48, 1443-1448.
91. Jbabdi S, Johansen-Berg H (2011) Tractography: Where do we go from here? Brain Connect 1, 169-183.
92. Gutman B, Leonardo C, Jahanshad N, Hibar D, Eschenburg K, Nir T, Villalon J, Thompson P (2014) Registering cortical surfaces based on whole-brain structural connectivity and continuous connectivity analysis. Med Image Comput Comput Assist Interv 17, 161-168.
93. Prescott JW, Guidon A, Doraiswamy PM, Roy Choudhury K, Liu C, Petrella JR, Alzheimer's Disease Neuroimaging I (2014) The Alzheimer structural connectome: Changes in cortical network topology with increased amyloid plaque burden. Radiology 273, 175-184.
94. Ensafi S, Shijian L, Kassim AA, Chew Lim T (2014) 3D reconstruction of neurons in electron microscopy images. Conf Proc IEEE Eng Med Biol Soc 2014, 6732-6735.
95. Folstein M (2007) Improving dementia assessment by reducing sample heterogeneity. Int Psychogeriatr 19, 383-389.
96. Mackay-Sim A (2013) Patient-derived stem cells: Pathways to drug discovery for brain diseases. Front Cell Neurosci 7, 29.
97. SaportaMA,GrskovicM,Dimos JT (2011) Induced pluripotent stem cells in the study of neurological diseases. Stem Cell Res Ther 2, 37.
98. Qiang L, Inoue K, Abeliovich A (2014) Instant neurons: Directed somatic cell reprogramming models of central nervous system disorders. Biol Psychiatry 75, 945-951.
99. Israel MA, Yuan SH, Bardy C, Reyna SM, Mu Y, Herrera C, Hefferan MP, Van Gorp S, Nazor KL, Boscolo FS, Carson CT, Laurent LC, Marsala M, Gage FH, Remes AM, Koo EH, Goldstein LS (2012) Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature 482, 216-220.
100. Kondo T, Asai M, Tsukita K, Kutoku Y, Ohsawa Y, Sunada Y, Imamura K, Egawa N, Yahata N, Okita K, Takahashi K, Asaka I, Aoi T,Watanabe A,Watanabe K, Kadoya C, Nakano R, Watanabe D, Maruyama K, Hori O, Hibino S, Choshi T, Nakahata T, Hioki H, Kaneko T, Naitoh M, Yoshikawa K, Yamawaki S, Suzuki S, Hata R, Ueno S, Seki T, Kobayashi K, Toda T, Murakami K, Irie K, Klein WL, Mori H, Asada T, Takahashi R, Iwata N, Yamanaka S, Inoue H (2013) Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Abeta and differential drug responsiveness. Cell Stem Cell 12, 487-496.
101. Ooi L, Sidhu K, Poljak A, Sutherland G, O'Connor MD, Sachdev P, Munch G (2013) Induced pluripotent stem cells as tools for disease modelling and drug discovery in Alzheimer's disease. J Neural Transm 120, 103-111.
102. VaccarinoFM,StevensHE,KocabasA,PalejevD,SzekelyA, GrigorenkoEL,WeissmanS(2011)Inducedpluripotentstem cells:Anewtooltoconfrontthechallengeofneuropsychiatric disorders. Neuropharmacology 60, 1355-1363.
103. Qiang L, Fujita R, Abeliovich A (2013) Remodeling neurodegeneration: Somatic cell reprogramming-based models of adult neurological disorders. Neuron 78, 957-969.
104. de Vries RB, Leenaars M, Tra J, Huijbregtse R, Bongers E, Jansen JA, Gordijn B, Ritskes-HoitingaM(2013) The potential of tissue engineering for developing alternatives to animal experiments: A systematic review. J Tissue Eng Regen Med doi: 10. 1002/term. 1703
105. Schlachetzki JC, Hull M (2009) Microglial activation in Alzheimer's disease. Curr Alzheimer Res 6, 554-563.
106. Walker DG, Lue LF (2005) Investigations with cultured human microglia on pathogenic mechanisms of Alzheimer's disease and other neurodegenerative diseases. J Neurosci Res 81, 412-425.
107. Huh D, Torisawa YS, Hamilton GA, Kim HJ, Ingber DE (2012) Microengineered physiological biomimicry: Organson-chips. Lab Chip 12, 2156-2164.
108. Sutherland ML, Fabre KM, Tagle DA (2013) The National Institutes of Health Microphysiological Systems Program focuses on a critical challenge in the drug discovery pipeline. Stem Cell Res Ther 4 Suppl 1, I1.
109. Abaci HE, Shuler ML (2015) Human-on-a-chip design strategies and principles for physiologically based pharmacokinetics/ pharmacodynamics modeling. Integr Biol (Camb) 7, 383-391.
110. Marx U, Walles H, Hoffmann S, Lindner G, Horland R, Sonntag F, Klotzbach U, Sakharov D, Tonevitsky A, Lauster R (2012) 'Human-on-a-chip' developments: A translational cutting-edge alternative to systemic safety assessment and efficiency evaluation of substances in laboratory animals and man? Altern Lab Anim 40, 235-257.
111. Grskovic M, Javaherian A, Strulovici B, Daley GQ (2011) Induced pluripotent stem cells-opportunities for disease modelling and drug discovery. Nat Rev Drug Discov 10, 915-929.
112. Pizzi R, Cino G, Gelain F, Rossetti D, Vescovi A (2007) Learning in human neural networks on microelectrode arrays. Biosystems 88, 1-15.
113. Dranias MR, Ju H, Rajaram E, VanDongen AM (2013) Short-term memory in networks of dissociated cortical neurons. J Neurosci 33, 1940-1953.
114. Rhinn H, Fujita R, Qiang L, Cheng R, Lee JH, Abeliovich A (2013) Integrative genomics identifies APOE epsilon4 effectors in Alzheimer's disease. Nature 500, 45-50.
115. Zahid S, Oellerich M, Asif AR, Ahmed N (2012) Phosphoproteome profiling of substantia nigra and cortex regions of Alzheimer's disease patients. J Neurochem 121, 954-963.
116. Graff-Radford J, Kantarci K (2013) Magnetic resonance spectroscopy in Alzheimer's disease. Neuropsychiatr Dis Treat 9, 687-696.
117. Mastroeni D, Grover A, Delvaux E, Whiteside C, Coleman PD, Rogers J (2011) Epigenetic mechanisms in Alzheimer's disease. Neurobiol Aging 32, 1161-1180.
118. Millan MJ (2014) The epigenetic dimension of Alzheimer's disease: Causal, consequence, or curiosity? Dialogues Clin Neurosci 16, 373-393.
119. Chetty M, Rose RH, Abduljalil K, Patel N, Lu G, Cain T, Jamei M, Rostami-Hodjegan A (2014) Applications of linking PBPK and PD models to predict the impact of genotypic variability, formulation differences, differences in target binding capacity and target site drug concentrations on drug responses and variability. Front Pharmacol 5, 258.
120. Poet TS, Timchalk C, Hotchkiss JA, Bartels MJ (2014) Chlorpyrifos PBPK/PD model for multiple routes of exposure. Xenobiotica 44, 868-881.
121. Santamaria AB (2008) Manganese exposure, essentiality & toxicity. Indian J Med Res 128, 484-500.
122. Salazar JG, Ribes D, Cabre M, Domingo JL, Sanchez-Santed F, Colomina MT (2011) Amyloid beta peptide levels increase in brain of AbetaPP Swedish mice after exposure to chlorpyrifos. Curr Alzheimer Res 8, 732-740.
123. Janson J, Eketjall S, Tunblad K, Jeppsson F, Von Berg S, Niva C, Radesater AC, Falting J, Visser SA (2014) Population PKPD modeling of BACE1 inhibitor-induced reduction in Abeta levels in vivo and correlation to in vitro potency in primary cortical neurons from mouse and guinea pig. Pharm Res 31, 670-683.
124. Rao PP, Mohamed T, Teckwani K, Tin G (2015) Curcumin binding to beta amyloid: A computational study. Chem Biol Drug Des. doi: 10. 1111/cbdd. 12552
125. Huang HJ, Chen HY, Lee CC, Chen CY (2014) Computational design of apolipoprotein E4 inhibitors for Alzheimer's disease therapy from traditional Chinese medicine. Biomed Res Int 2014, 452625.
126. Jin N, Qian W, Yin X, Zhang L, Iqbal K, Grundke-Iqbal I, Gong CX, Liu F (2013) CREB regulates the expression of neuronal glucose transporter 3: A possible mechanism related to impaired brain glucose uptake in Alzheimer's disease. Nucleic Acids Res 41, 3240-3256.
127. Vukic V, Callaghan D,Walker D, Lue LF, Liu QY, Couraud PO, Romero IA, Weksler B, Stanimirovic DB, Zhang W (2009) Expression of inflammatory genes induced by betaamyloid peptides in human brain endothelial cells and in Alzheimer's brain is mediated by the JNK-AP1 signaling pathway. Neurobiol Dis 34, 95-106.
128. Gan X, Huang S, Wu L, Wang Y, Hu G, Li G, Zhang H, Yu H, Swerdlow RH, Chen JX, Yan SS (2014) Inhibition of ERK-DLP1 signaling and mitochondrial division alleviates mitochondrial dysfunction in Alzheimer's disease cybrid cell. Biochim Biophys Acta 1842, 220-231.
129. Esposito G, Scuderi C, Lu J, Savani C, De Filippis D, Iuvone T, Steardo L Jr, Sheen V, Steardo L (2008) S100B induces tau protein hyperphosphorylation via Dickopff-1 up-regulation and disrupts the Wnt pathway in human neural stem cells. J Cell Mol Med 12, 914-927.
130. Gibb S (2008) Toxicity testing in the 21st century: A vision and a strategy. Reprod Toxicol 25, 136-138.
131. van der Worp HB, Howells DW, Sena ES, Porritt MJ, Rewell S, O'Collins V, Macleod MR (2010) Can animal models of disease reliably inform human studies? PLoS Med 7, e1000245.
132. Begley CG, Ellis LM (2012) Drug development: Raise standards for preclinical cancer research. Nature 483, 531-533.
133. Geerts H (2009) Of mice and men: Bridging the translational disconnect in CNS drug discovery. CNS Drugs 23, 915-926.
134. Mak IW, Evaniew N, Ghert M (2014) Lost in translation: Animal models and clinical trials in cancer treatment. Am J Transl Res 6, 114-118.
135. National Institutes of Health (2013) NIH to reduce significantly the use of chimpanzees in research, http://www. nih. gov/news/health/jun2013/od-26. htm, Accessed May 19, 2015.
136. Ogishima S, Mizuno S, Kikuchi M, Miyashita A,Kuwano R, Tanaka H, Nakaya J (2013) A map of Alzheimer's diseasesignaling pathways: A hope for drug target discovery. Clin Pharmacol Ther 93, 399-401.
137. Calitz C, Pollack KM, Millard C, Yach D (2015) National institutes of health funding for behavioral interventions to prevent chronic diseases. Am J Prev Med 48, 462-471.
138. Reid AT, Evans AC (2013) Structural networks in Alzheimer's disease. Eur Neuropsychopharmacol 23, 63-77.